BioSpace News Archive

Florida Cancer Specialists & Research Institute, LLC leaders and pharmacy experts will share insights and best practices in specialty pharmacy operations and dispensing that are contributing to positive patient outcomes at the NCODA 2024 Spring Forum in Dallas.

Vancouver, British Columbia--(Newsfile Corp. - April 3, 2024) - Solarvest BioEnergy Inc. (TSXV: SVS) (“Solarvest” or the “Company”) is pleased to announce that it intends to hold its annual general meeting of shareholders (the “Meeting”) on May 10, 2024 in Vancouver, British Columbia.

In the rapidly growing field of the global next generation sequencing market size was valued at USD 9.19 billion in 2023 and is projected to reach USD 66.04 billion by 2033, growing at a CAGR of 21.8% from 2024 to 2033 according to a new report by Nova One Advisor.

Inventiva announced that it had filed its 2023 Universal Registration Document for the year ended December 31, 2023, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers” and its 2023 Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission.

QIAGEN N.V. announced a series of new products to further enhance cancer research as well as to enable urine collection and stabilization as a new approach for liquid biopsy.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, announced that the company granted equity awards to 30 new employees, in each case with a grant date of April, 1 2024, as equity inducement awards under the terms of the company’s 2023 Inducement Plan.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies, announced its participation in two upcoming investor conferences:

Today, the U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis; adults with acute bacterial skin and skin structure infections (ABSSSI); and adult and pediatric patients three months to less than 18 years old with community-acquired bacterial pneumonia (CABP).

The urine sediment examination is primarily used to detect and assess kidney and urinary system health. In the conventional practice, a urine sediment test covers six items: red blood cells, white blood cells, squamous cells, urinary casts, crystals, and bacteria, while urine bacterial culture and pathological diagnostics may require an additional week.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder.